We have also confirmed an interim dividend of $0.93, reflecting the Board’s intention to increase the dividend to $2.90 for the full year of 2022. Looking across our business, we delivered revenue growth from all disease areas, reflecting not only the breadth of our portfolio, but also the...
Our share position has held strong as we've seen the entrance of new competition within the class. In the second-line setting, as I mentioned in my prepared remarks, we have seen erosion of our share in that relapsed/refractory setting, particularly within the naive. We remain, as we see...